MeiraGTx (Nasdaq: MGTX), has announced two pre-clinical programs addressing Inherited Retinal Diseases (IRDs) caused by mutations in KCNV2 and GUCY2D, for cone-dystrophy, and are presented with… Read More »MeiraGTx (NASDAQ: MGTX), a UK gene therapy company, has announced two novel IRD research programs on gene therapy
The US FDA has approved a 100 mg/mL ocular implant (Port Delivery System) for the treatment of nAMD, sponsored by Roche (SIX: RO, ROG; OTCQX:… Read More »FDA has approved an implant (Port Delivery System with ranibizumab) to treat neovascular age-related macular degeneration (nAMD)
Editas Medicine, Inc. (NASDAQ: EDIT) has announced positive initial clinical data from an ongoing, open label Phase I/II “BRILLIANCE” study EDIT-101, a CRISPR-based experimental treatment… Read More »Editas Medicine, Inc. (NASDAQ; EDIT) has announced positive clinical data on their CRISPR gene therapy product on LCA10
Novartis International AG (SIX: NOVN; NYSE: NVS) has announced the acquisition of Arctos Medical, adding a pre-clinical optogenetics-based AAV gene therapy program and Arctos’ proprietary… Read More »Novartis Institutes for BioMedical Research (NIBR) announces the acquisition of Arctos Medical on optogenetics treatments
In their press release, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced that an ongoing Phase II proof-of-concept trial evaluating an investigational 8 mg dose of… Read More »Regeneron announces that its high-dose aflibercept (8mg) has met primary end-point in Phase II data for wet AMD.
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus”) and reVision Therapeutics, Inc. (“reVision”) have announced a collaboration on the development of a therapy for Stargardt… Read More »Aequus Pharmaceuticals Inc and reVision Therapeutics collaborate on Stargardt disease therapy treatment.
Nanoscope Therapeutics Inc., a company based in Bedford, Texas, has reported vision improvements for advanced retinitis pigmentosa (RP) patients after one year following a single… Read More »Nanoscope Therapeutics Inc., have announced positive results from a phase 1/2a study for optogenetic therapy
GenSight Biologics (Euronext: SIGHT), announced that the French Competent Authority, the National Agency for Medicines and Health Products Safety (Agence Nationale de Sécurité du Médicament… Read More »GenSight Biologics has received approval for “LUMEVOQ” for LHON (with ND4 mutations) for a Cohort Temporary Authorization for use in France
Genentech (Roche Group [SIX: RO, ROG; OTCQX: RHHBY]), has announced that the U.S. FDA has accepted a Biologics License Application (BLA), under priority review, for… Read More »Genentech (Roche [SIX: RO, ROG; OTCQX: RHHBY]) has submitted a “Port Delivery System” with ranibizumab for the treatment of wet/neovascular age-related macular degeneration (nAMD)
REGENXBIO Inc. (Nasdaq: RGNX), a clinical-stage biotechnology company has reported that 42 patients have been enrolled in the RGX- 314-001 study (NCT03066258) with up to… Read More »Regenxbio Inc. has reported interim results of >40 patients dosing of Phase II for RGX-314 gene therapy treatment for wet AMD